Similarly in business, if a senior biopharma executive was forced every day to step through even of fraction of the actual complexity of the science associated with every product, it would be overwhelming, and make decision-making all but impossible.
In 2002, the FDA warned consumers about reports of liver damage associated with kava, but the agency stopped short of pulling the product from shelves -- a step that public health officials in other countries have taken.